Comment on

• Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

  Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Kinney TR, et al. Blood. 1999 Sep 1;94(5):1550-4. Blood. 1999. PMID: 10477679 Clinical Trial.
• Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

  Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, Devalck C, Dresse MF, Feremans W, Hunninck K, Toppet M, Philippet P, Van Geet C, Sariban E. Ferster A, et al. Blood. 2001 Jun 1;97(11):3628-32. doi: 10.1182/blood.v97.11.3628. Blood. 2001. PMID: 11369660
• Is hydroxyurea leukemogenic in children with sickle cell disease?

  de Montalembert M, Davies SC. de Montalembert M, et al. Blood. 2001 Nov 1;98(9):2878-9. doi: 10.1182/blood.v98.9.2878. Blood. 2001. PMID: 11697339 No abstract available.
• Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

  Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K. Ware RE, et al. Blood. 2002 Jan 1;99(1):10-4. doi: 10.1182/blood.v99.1.10. Blood. 2002. PMID: 11756146 Clinical Trial.